-
公开(公告)号：US20250066506A1
公开(公告)日：2025-02-27
申请号：US18596319
申请日：2024-03-05
Applicant: GENMAB A/S
Inventor： Bart DE GOEIJ , Patrick VAN BERKEL , Kristin STRUMANE , Aran Frank LABRIJN , Joost J. NEIJSSEN , Joyce I. MEESTERS , Paul PARREN , Janine SCHUURMAN
Abstract: Bispecific antibodies which comprise antigen-binding regions binding to two different epitopes of human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and methods of preparing and using the antibodies are also disclosed.
-
公开(公告)号：US20250064969A1
公开(公告)日：2025-02-27
申请号：US18940614
申请日：2024-11-07
Applicant: Suntec Medical, Inc.
Inventor： Chun-Ting Cheng , Yuan-Chung Tsai , Pauline Ying Lau
Abstract: The present invention provides a method of treating an autoimmune disease including type 1 diabetes, inflammatory bowel disease, rheumatoid arthritis. multiple sclerosis, systemic lupus erythematosus, psoriasis, myasthenia Gravis, and Hashimoto's thyroiditis. The method comprises the step of administering to a subject in need thereof an effective amount of micelles having an outer shell comprising one or more polymer-flavonoid conjugates, optionally an inner shell comprising one or more flavonoid oligomer, and a drug encapsulated within the shells. The present invention also provides a method of treating an autoimmune disease by administering to a subject in need thereof an effective amount of one or more polymer-flavonoid conjugate or one or more flavonoid oligomers.
-
公开(公告)号：US20250059297A1
公开(公告)日：2025-02-20
申请号：US18724021
申请日：2023-01-19
Inventor： Chengzhang Shang , Liu Yang , Yanfei Han , Yuelei Shen
Abstract: Provided are anti-HER2 antibodies or antigen binding fragments thereof, anti-TROP2 antibodies or antigen binding fragments thereof, antigen-binding protein constructs (e.g., bispecific antibodies or antigen-binding fragments thereof) that specifically bind to two different antigens (e.g., HER2 and TROP2), and antibody drug conjugates.
-
公开(公告)号：US12213958B2
公开(公告)日：2025-02-04
申请号：US16764821
申请日：2018-11-15
Applicant: Research Cancer Institute of America
Inventor： Mohammed Amin Nezami
IPC: A61K31/352 , A61K31/192 , A61K31/436 , A61K31/454 , A61K31/506 , A61K31/517 , A61K31/519 , C07K16/22 , C07K16/28 , C07K16/32 , A61K9/00 , A61K9/51 , B82Y5/00
Abstract: Provided herein are compositions, methods, systems and/or kits for preventing and/or treating neoplasms using at least one modulator selected from quercetin, sodium phenyl butyrate and epigallocatechin-3-gallate in combination with one or more anti-cancer agents. The compositions, methods, systems and/or kits are used to prevent and/or treat neoplasms that are resistant to the one or more anti-cancer agents when administered alone. Also provided are nanoformulations based on nanoparticles with one or more anti-cancer agents and/or one or more modulators for preventing and/or treating neoplasms.
-
公开(公告)号：US20250026852A1
公开(公告)日：2025-01-23
申请号：US18672417
申请日：2024-05-23
Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHA
Inventor： Tomoyuki IGAWA , Hiroyuki ISHIKAWA , Naoka HIRONIWA , Tatsuya KAWA
Abstract: The present invention relates to polypeptides containing an antigen-binding domain and a carrying moiety having an inhibiting domain that inhibits the antigen-binding activity of the antigen-binding domain, and having a longer half-life than that of the antigen-binding domain existing alone; methods for producing and screening for the polypeptides; pharmaceutical compositions containing the polypeptide; methods for producing and screening for a single-domain antibody whose antigen-binding activity is inhibited by its association with particular VL, VH or VHH; and fusion polypeptide libraries including a single-domain antibody whose antigen-binding activity is inhibited by its association with particular VL, VH or VHH.
-
Patent Agency Ranking
公开(公告)号：US20250026841A1
公开(公告)日：2025-01-23
申请号：US18708551
申请日：2022-11-18
Applicant: AP Biosciences, Inc.
Inventor： Jeng-Horng Her , Po-Lin Huang , Hsin-Ta Hsieh , Ching-Hsuan Hsu , Jhong-Jhe You
Abstract: Provided herein are antibodies or antigen binding fragments thereof having a binding specificity for p95HER2 or for CD73, bispecific antibodies comprising a first antigen binding region that binds to p95HER2 or CD73 and a second antigen binding region that binds to an immune checkpoint molecule or an immune stimulatory molecule, and antibody-drug conjugates thereof. Also provided herein are pharmaceutical compositions comprising the antibodies, antigen binding fragments thereof, bispecific antibodies or antibody drug conjugates thereof, and methods of use thereof. The methods of use include method of treating cancer.
-
公开(公告)号：US20250019462A1
公开(公告)日：2025-01-16
申请号：US18900599
申请日：2024-09-27
Applicant: NEX-I, INC.
Inventor： Kyoung Wan YOON , Kyungjin BOO , Jeongmin RYOO , Jinyoung SOHN , Junho YEOM , Sujin KIM
Abstract: The present invention relates to an antibody specifically binding to apoptosis inhibitor 5 (API5) protein and uses thereof. The antibody or antigen-binding fragment thereof that specifically binds to APIS according to the present invention can have excellent anticancer effects, such as inhibiting phosphorylation of ERK in cancer cells and inhibiting cancer growth. In addition, the antibody or antigen-binding fragment thereof exhibits excellent anticancer effects against cancers that are resistant or refractory to anticancer drugs. Accordingly, it is useful for preventing or treating cancers resistant or refractory to anticancer drugs as well as general cancers.
-
公开(公告)号：US20250019444A1
公开(公告)日：2025-01-16
申请号：US18894660
申请日：2024-09-24
Applicant: Dragonfly Therapeutics, Inc.
Inventor： Gregory P. Chang , Ann F. Cheung , Asya Grinberg , William Haney , Bradley M. Lunde , Bianka Prinz
Abstract: Antibody heavy chain variable domains that can be paired with antibody light chain variable domains to form an antigen-binding site targeting the NKG2D receptor on natural killer cells are described. Proteins comprising an NKG2D antigen-binding site, pharmaceutical compositions and therapeutic methods thereof, including for the treatment of cancer, are also described.
-
公开(公告)号：US20250018051A1
公开(公告)日：2025-01-16
申请号：US18708861
申请日：2022-11-04
Applicant: NERVIANO MEDICAL SCIENCES S.R.L.
Inventor： Matteo SALSA , Fabio GASPARRI , Paolo ORSINI , Barbara VALSASINA
Abstract: The present invention provides anthracycline-linker reagents for the preparation of therapeutic antibody-drug conjugate (ADC) compounds.
The present invention also provides therapeutic antibody-drug conjugate (ADC) compounds comprising anthracycline drug moieties, with biological activity against cancer cells. The compounds may inhibit tumor growth in mammals and may be useful for treating human cancer patients.
Aspects of the invention include methods of making, methods of preparing, methods of synthesis, methods of conjugation, and methods of purification of the anthracycline-linker reagents and of the antibody-drug conjugate compounds.-
公开(公告)号：US20250018040A1
公开(公告)日：2025-01-16
申请号：US18710726
申请日：2022-12-16
Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Servic
Inventor： Ira H. Pastan , Masanori Onda , Mitchell Ho , Xiu-fen Liu , Tapan Bera , Anirban Chakraborty
Abstract: Polypeptides, proteins, and chimeric antigen receptors (CARs) that specifically bind to human mesothelin582-598 (IP-NGYLVLDLSMQEALS) (SEQ ID NO: 1) are disclosed. Anti-mesothelin binding moieties, nucleic acids, recombinant expression vectors, host cells, populations of cells, pharmaceutical compositions, and conjugates relating to the poly peptides, proteins, and CARS are disclosed. Methods of reducing mesothelin shed from cell membranes, methods of detecting the presence of cancer, and methods of treating or preventing cancer are also disclosed.
-
-
-
-
-
-
-
-
-
Search Results
3969
records
(took 0.034 seconds)
